Thompson Travis Alvin sold $4K of BCYC
Thompson Travis Alvin (Chief Financial Officer) sold 923 shares of BICYCLE THERAPEUTICS PLC (BCYC) at an average of $4.27 ($4.27–$4.31) across 2 trades over 2026-07-02 to 2026-07-06.
How this was made
The 30-second read
Why it matters
The newest fact is the CFO’s open-market sale details (dates, share count, price range, and post-sale holdings), which may affect short-term sentiment but not fundamentals.
Market read
Traders may monitor for follow-on insider activity, but this specific filing does not introduce new business or clinical information.
What to watch
Insider sales can be driven by diversification, taxes, or pre-existing personal liquidity needs; the article provides no rationale for the sale.
Background
The article is a primary-source SEC Form 4 insider transaction disclosure for Bicycle Therapeutics PLC.
Ticker impact
Bicycle Therapeutics CFO Thompson Travis Alvin sold 923 shares in open-market trades at about $4.27–$4.31, per Form 4 filed July 7.
Likely minimal near-term impact; any reaction would be sentiment-driven rather than based on new operating information.
The filing provides transaction details (size, price range, holdings after), but no accompanying company-specific catalyst (earnings, guidance, trial, deal, or regulatory action).
Market effects
No clear sector read-through; insider sales are company-specific and not tied to a broader biotech catalyst in the text.
None indicated.
None indicated.
Counterpoint
Absence of a 10b5-1 plan could be interpreted as less “scheduled” selling, which some traders may view as mildly bearish despite the small size.
Key entities
- issuerBicycle Therapeutics PLC
Subject of the Form 4 insider transaction; CFO sold shares as disclosed.
- insiderThompson Travis Alvin
Chief Financial Officer who executed the open-market sale(s).